BALDUZZI, SILVIA
 Distribuzione geografica
Continente #
NA - Nord America 321
EU - Europa 188
AS - Asia 108
SA - Sud America 1
Totale 618
Nazione #
US - Stati Uniti d'America 317
IE - Irlanda 107
CN - Cina 80
SG - Singapore 26
IT - Italia 24
DE - Germania 21
FI - Finlandia 15
BE - Belgio 7
CA - Canada 4
CZ - Repubblica Ceca 3
GB - Regno Unito 2
LT - Lituania 2
RU - Federazione Russa 2
SE - Svezia 2
BR - Brasile 1
FR - Francia 1
ID - Indonesia 1
IR - Iran 1
NL - Olanda 1
RO - Romania 1
Totale 618
Città #
Dublin 105
Chandler 70
Ashburn 52
Singapore 23
Shanghai 19
Boardman 17
Helsinki 14
Lawrence 13
Medford 13
Princeton 13
Nanjing 12
New York 12
Beijing 10
Washington 9
Brussels 7
Munich 5
Wilmington 5
Changsha 4
Galliate 4
Guangzhou 4
Milan 4
Nanchang 4
Norwalk 4
Seattle 4
Shenyang 4
Toronto 4
Brno 3
Los Angeles 3
Pavia 3
Ann Arbor 2
Berlin 2
Fairfield 2
Frankfurt am Main 2
Hebei 2
Jacksonville 2
Jiaxing 2
London 2
Matera 2
Monzambano 2
Shijiazhuang 2
Woodbridge 2
Chicago 1
Dallas 1
Falkenstein 1
Gunzenhausen 1
Haikou 1
Hangzhou 1
Hengyang 1
Kunming 1
Messina 1
Philadelphia 1
Piscataway 1
Saint Petersburg 1
Santa Clara 1
Serramanna 1
Wuhan 1
Totale 483
Nome #
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 57
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 57
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 55
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 50
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 49
Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study 42
Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis 42
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature 42
Retention rate of IL-1 inhibitors in Schnitzler's syndrome 39
Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease 36
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study 35
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies 34
Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection 33
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 27
Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 24
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 16
Correction to: Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 11
Totale 649
Categoria #
all - tutte 3.841
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.841


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 0 0 0 0 0 1 1 5 5 0
2020/202114 0 0 1 0 0 0 1 3 4 0 4 1
2021/202258 0 0 3 1 5 2 2 4 1 2 8 30
2022/2023253 24 26 1 9 15 19 0 14 120 1 9 15
2023/2024185 17 25 12 8 23 47 6 16 5 17 4 5
2024/202589 11 20 5 10 9 34 0 0 0 0 0 0
Totale 649